Search hospitals

>

Ontario

>

TORONTO

Princess Margaret Cancer Centre

Claim this profile

TORONTO, Ontario M5G 2M9

Global Leader in Cancer

Global Leader in Lung Cancer

Conducts research for Pancreatic Cancer

Conducts research for Breast Cancer

Conducts research for Prostate Cancer

988 reported clinical trials

71 medical researchers

Photo of Princess Margaret Cancer Centre in TORONTOPhoto of Princess Margaret Cancer Centre in TORONTO

Summary

Princess Margaret Cancer Centre is a medical facility located in TORONTO, Ontario. This center is recognized for care of Cancer, Lung Cancer, Pancreatic Cancer, Breast Cancer, Prostate Cancer and other specialties. Princess Margaret Cancer Centre is involved with conducting 988 clinical trials across 548 conditions. There are 71 research doctors associated with this hospital, such as Amit Oza, MD, Lillian Siu, MD, Marcus Butler, and Philippe Bedard.

Area of expertise

1

Cancer

Global Leader

Princess Margaret Cancer Centre has run 208 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage III
HER2 positive
2

Lung Cancer

Global Leader

Princess Margaret Cancer Centre has run 148 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage III
HER2 positive

Top PIs

Clinical Trials running at Princess Margaret Cancer Centre

Breast Cancer

Cancer

Lung Cancer

Multiple Myeloma

Ovarian Cancer

Colorectal Cancer

Lymphoma

Head and Neck Cancers

Prostate Cancer

Solid Tumors

Image of trial facility.

Sacituzumab Tirumotecan + Pembrolizumab

for Breast Cancer

Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sacituzumab tirumotecan alone or with pembrolizumab live longer overall or without the cancer growing or spreading compared to people treated with chemotherapy.

Recruiting

2 awards

Phase 3

3 criteria

Image of trial facility.

Sacituzumab Tirumotecan + Pembrolizumab

for Breast Cancer

The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) unresectable locally advanced, or metastatic, breast cancer. The primary hypotheses are that sacituzumab tirumotecan as a single agent and sacituzumab tirumotecan plus pembrolizumab are superior to TPC with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR) in all participants.

Recruiting

2 awards

Phase 3

3 criteria

Image of trial facility.

sac-TMT + Pembrolizumab

for Breast Cancer

This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative breast cancer (TNBC) who received neoadjuvant therapy and did not achieve a pathological complete response (pCR) at surgery. The primary objective is to compare sacituzumab tirumotecan plus pembrolizumab to TPC (pembrolizumab or pembrolizumab plus capecitabine) with respect to invasive disease-free survival (iDFS) per investigator assessment. It is hypothesized that sacituzumab tirumotecan plus pembrolizumab is superior to TPC with respect to iDFS per investigator assessment.

Recruiting

2 awards

Phase 3

5 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Princess Margaret Cancer Centre?

Where is Princess Margaret Cancer Centre located?

Who should I call to ask about financial aid or insurance network?

What insurance does Princess Margaret Cancer Centre accept?

What awards or recognition has Princess Margaret Cancer Centre received?